New Content  edit
Get The App!

Loading the player...
RESPITE Study Results
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
Recent advances in pulmonary hypertension have led to evolution of strategic approaches to treatment. In patients on therapy, who are exhibiting a decline in function, escalation of combination therapy has been a standard method. The recent RESPITE trial, however, explored the switch of patients, failing on PDE5 inhibitor therapy, to the soluble guanylate cyclase inhibitor, riociguat. Dr. James White describes the rationale, design and principal efficacy and safety results of this important study.